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In this issue of Cancer Cell, Weischenfeldt and colleagues report on the whole genome sequencing of
11 early-onset prostate cancers. Compared to elderly onset prostate cancer, these tumors demonstrate
enrichment for androgen-driven structural rearrangements involving ETS family genes. This study confirms
observations that prostate cancer manifests discrete genomic subclasses.Prostate cancer remains the most
common type of cancer and a frequent
cause of cancer-related mortality in men
worldwide. Although prostate cancer
predominantly affects oldermen, a subset
of prostate cancer arises inmen below the
age of 50. Early-onset cancers often
display hereditary links to germline muta-
tions; well-known examples include
BRCA2 mutations in breast and ovarian
cancers and p53mutations in Li-Fraumeni
syndrome. Among common solid tumors,
prostate cancer has been shown to
have the largest estimated effect of herita-
bility (Lichtenstein et al., 2000). Despite
suggestions that hereditary prostate
cancer genes exist, most studies have
failed to yield reproducible germline
variants that account for early onset
prostate cancer. Rare germline variants
have been discovered, such as in
HOXB13, but may only account for a
small percentage of early-onset prostate
cancer cases. No single germline variant
accounts for a substantial proportion of
prostate cancer.
In the search for a genetic basis for
early-onset prostate cancer, Weischen-
feldt et al. (2013) describe, in this issue
of Cancer Cell, whole genome se-
quencing of 11 early-onset prostate
cancer (median age 47 years) selectedfrom a German cohort. They compared
their results to seven previously published
whole genomes meeting their definition
for elderly-onset prostate cancer (median
age of 65 years) (Berger et al., 2011).
A side-to-side evaluation revealed a
statistically significant increase in somatic
structural rearrangements (SRs) in
general and balanced rearrangements in
particular in the 11 early onset-prostate
cancer tumors as compared to the
elderly-onset prostate cancer tumors.
Interestingly, 91% (10/11) early-onset
prostate cancer harbored an ETS gene re-
arrangement involving either ERG (n = 9)
or ETV1 (n = 1), which is significantly
higher than the estimated 50% for all
prostate cancers (Rubin et al., 2011; Tom-
lins et al., 2005).
Androgen stimulation and genotoxic
stress (e.g., radiation) have previously
been shown to induce the TMPRSS2-
ERG gene fusion, themost common pros-
tate cancer ETS rearrangement (Mani
et al., 2009). By exploiting a map of
publicly available androgen receptor
(AR) binding sites, Weischenfeldt et al.
(2013) observed that the early-onset pros-
tate cancer tumors exhibited SR break
points situated nearer to AR binding sites
than those in the seven elderly-onset
prostate cancer tumors from BergerCancer Cell 23,et al. (2011). This finding raises the possi-
bility that androgen stimulation preferen-
tially induces certain types of SRs in
early-onset prostate cancer, leading to
a cascade of oncogenic molecular events
such as recurrent ETS rearrangements.
The authors conclude that early-onset
prostate cancer may be more likely to
harbor androgen-driven SRs, whereas
elderly onset prostate cancers display
a distinct rearrangement landscape.
The notion that androgen-triggered
DNA damage might explain the majority
of early-onset prostate cancer is certainly
intriguing. However, comprehensive as-
sessment of causal components should
also account for how prostate cancer is
often diagnosed. Today, most prostate
cancer is detected through prostate-
specific antigen (PSA) screening. Wide-
spread screening has increased the
detection of low risk cancers. In fact,
recent U.S. and European screening
studies have questioned if the benefits
of PSA screening outweigh the attendant
morbidities and costs. Relevant to the
Weischenfeldt et al. (2013) study, prostate
cancer detected by PSA screening may
be diagnosed up to 15 years earlier than
may have been the case without PSA
screening. Thus, a 50-year-old man diag-
nosed with prostate cancer by PSAFebruary 11, 2013 ª2013 Elsevier Inc. 133
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Figure 1. Comparison of PSA Levels and ETS Rearrangement Frequencies of the 11 Cases
from the Weischenfeldt and Colleagues Study and Data from the Tyrol PSA Screening
Population
(A) Significantly higher PSA levels were found in theWeischenfeldt et al. (2013) cases than observed in the
Tyrol PSA screening population of men with prostate cancer. The width of the boxes reflects differences in
sample sizes: the dotted horizontal gray line corresponds to 4 ng/ml, and age indicates years.
(B) The percentage of ETS rearrangement positive prostate cancer in the 11 whole genomes from the
Weischenfeldt et al. (2013) study is shown compared to men from the Tyrol screening cohort stratified
by age. The numbers at the top of each bar indicates the percent of cases that are ETS positive.
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Previewsscreening might not have presented
clinically until he was 65 years old. In
such a case, the ‘‘early onset’’ versus
‘‘elderly onset’’ comparison might repre-
sent a distinction without a difference.
PSA vagaries aside, results of the
Weischenfeldt et al. (2013) study also
suggest that the constellation of genomic
alterations (i.e., increased somatic
androgen-related SRs and ETS rear-
rangements) influence earlier clinical
detection.We recently completed a popu-
lation-based study determining ERG
overexpression, used as a surrogate for
ERG rearrangements, in 1,039 radical
prostatectomy tumor samples from the
Tyrol PSA screening cohort (Schaefer
et al., 2013). This study showed that early
ERG rearranged tumors manifest clini-
cally at lower PSA levels, and their preva-
lence is age-dependent. Figure 1 shows
the comparison of PSA levels and the
ETS/ERG rearrangement frequencies of
the 11 cases from the Weischenfeldt
et al. (2013) study with the Tyrol PSA
screening population, distinguishing
between men of 50 years of age at diag-
nosis or younger versus patients above
50 years of age and using the cutoff134 Cancer Cell 23, February 11, 2013 ª2013defined by Weischenfeldt et al. (2013).
Their ten ETS rearrangement positive
cases demonstrate significantly higher
PSA levels than those observed in pros-
tate cancer cases in the Tyrol PSA
screening population. The higher PSA
level, high tumor grade, and stage might
therefore reflect a particularly virulent
subset of prostate cancer identified from
a larger population of men with early-
onset disease diagnosed by PSA
screening. The question of whether or
not a similar virulent, high-PSA subset
may also exist among elderly prostate
cancer patients—and at what preva-
lence—will be an important follow-up
question.
A corollary of the Weischenfeldt et al.
(2013) study findings posits that SRs
arising from androgen-driven DNA
damage also give rise to the TMPRSS2-
ERG (and other ETS) rearrangements.
This important study extends previous
work that ETS-rearranged prostate
cancer comprises a distinct molecular
subclass. The TMPRSS2-ERG rearrange-
ment can be observed in the prostate
cancer precursor lesion (Perner et al.,
2006) and is associated with distinctElsevier Inc.somatic copy number aberrations (Demi-
chelis et al., 2009). TMPRSS2 is highly
androgen regulated and drives ERG
expression in the fusion gene. Berger
et al. (2011) noted that ERG-rearrange-
ment positive cases contained somatic
SR breakpoints located near AR binding
sites, whereas ETS-negative prostate
cancer harbored SR breakpoints signifi-
cantly distant from AR binding sites.
They also observed that these SRs in
ERG rearranged tumors could exist as
interwoven chains that involved cancer
related genes, suggesting a possible
selective growth advantage (Berger
et al., 2011). More recent work suggests
that ERG overexpression may mediate
three-dimensional DNA conformational
changes through active transcription,
putatively facilitating SRs under geno-
toxic conditions (Rickman et al., 2012).
The Weischenfeldt et al. (2013) study
now suggests an alternative scenario
where androgenic events drive SRs,
which leads to ETS rearrangements. This
would imply the early-onset ‘‘gene’’ might
really represent a susceptibility to andro-
genic DNA damage.
Disentangling the effect of cancer
screening from age may prove chal-
lenging for the foreseeable future, given
widespread PSA testing. Regardless,
Weischenfeldt et al. (2013) confirm obser-
vations that prostate cancer manifests
discrete genomic subclasses. The telltale
molecular fingerprints are emerging
through advances in whole genome se-
quencing that encompass important non-
coding regulatory regions not captured by
exome sequencing and innovations in
large data analysis. Future studies should
help elucidate the genomic events predis-
posing to androgen-driven SR break-
points, genomic events that may trigger
a cascade of prostate cancer alterations
including the recurrent TMPRSS2-ERG
rearrangements, and the development of
balanced chained loop rearrangements.
One can imagine that germline polymor-
phisms (i.e., SNPs or copy number vari-
ants) could deleteriously hinder DNA
repair mechanisms, thus phenocopying
BRCA2 deficiency. Epigenetic or environ-
mental effects may play some modify-
ing role in this process. Knowledge of
somatic SRs may also have important
implications with regards to diagnosis
and response to targeted treatment
after disease progression. Overall, the
Cancer Cell
PreviewsWeischenfeldt et al. (2013) study extends
a growing paradigm regarding the links
between complex rearrangements and
prostate carcinogenesis, while also con-
sidering the age dimension as a possible
player in the spectrum of clinical features
that contribute to disease biology.
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Normal and neoplastic tissues display cellular hierarchies that integrate extracellular cues to maintain tissue
function through bidirectional signals mediated via cell surface proteins. Two papers in Cancer Cell, one in
this issue (Day and colleagues) and one in a recent issue (Binda and colleagues), describe how Eph receptor
tyrosine kinases critically define and regulate the growth of cancer stem cells.Tumors display cellular heterogeneity
through the integration of multiple sup-
portive cell types—vasculature, stroma,
and immune components—as well as
diversity within the neoplastic compart-
ment derived from genetic and epigenetic
variability. Cancers co-opt transcriptional
programs normally active in development
and wound responses, processes in
which stem and progenitor cells con-
tribute, so it is not surprising that cancers
display characteristics of stem and
progenitor cells.
Recent data from human and murine
models support the presence of cellularhierarchies in some advanced cancers
with cancer stem cells (CSC) at the apex
(Chen et al., 2012; Singh et al., 2004).
The CSC field currently lacks a coherent
set of criteria to define these cells. Many
reports mistakenly hold that CSCs simply
represent cells that form spheres in
culture and tumors upon transplantation
(i.e., tumor initiating cells). Rather, CSCs
also mimic normal stem cells to create
a dysfunctional cellular hierarchy with
non-tumorigenic cells derived from the
self-renewing CSC. To fulfill this feature,
the CSC hypothesis needs to employ
strategies to prospectively segregatetumorigenic and non-tumorigenic cells
or perform functional lineage tracing
studies. A critical aspect of these studies
is the requirement to identify and separate
discrete populations and perform func-
tional analyses. In response, researchers
have defined a number of surface mole-
cules that are preferentially expressed
by CSCs and can be interrogated in live
cells. At first blush, the increasing number
of these markers may engender skepti-
cism as to the validity of the CSC hypoth-
esis, but this viewpoint is derived from our
desire to impose simplicity on an inher-
ently complex and dynamic system. First,February 11, 2013 ª2013 Elsevier Inc. 135
